



Please join us for an upcoming program

DISCOVER THE IMPACT OF GEMTESA: A Selective β_3 -Adrenergic Agonist for Effective OAB Treatment

FACULTY

MATT ROSENBERG MD
Medical Director
Mid-Michigan Center for Continence; Mid-Michigan Health
Centers; Mid-Michigan Center for Men's Health
Jackson, MI

RSVP TO

Carrie Porter
+1 (774) 405-5117
carrie.porter@us.sumitomo-pharma.com

DATE/TIME

Tuesday, May 19, 2026
6:30 PM (GMT-04:00) Eastern Daylight Time
(America/New_York)

LOCATION

Ruth's Chris Steak House
187 Monroe Avenue Northwest
Grand Rapids, Michigan
(616) 776-6426

RSVP BY

*Please respond as soon as possible as
space is limited 1-833-245-3178*

• overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adult males on pharmacological therapy for benign prostatic hyperplasia (BPH).

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

GEMTESA is contraindicated in patients with known hypersensitivity to vibegron or any components of the product. Hypersensitivity reactions, such as angioedema, have occurred.

WARNINGS AND PRECAUTIONS

Urinary Retention

Urinary retention has been reported in patients taking GEMTESA. The risk of urinary retention may be increased in patients with bladder outlet obstruction and also in patients taking muscarinic antagonist medications for the treatment of OAB. Monitor patients for signs and symptoms of urinary retention, particularly in patients with bladder outlet obstruction or patients taking muscarinic antagonist medications for the treatment of OAB. Discontinue GEMTESA in patients who develop urinary retention.

Angioedema

Angioedema of the face and/or larynx has been reported with GEMTESA. Angioedema has been reported to occur hours after the first dose or

after multiple doses. Angioedema, associated with upper airway swelling, may be life-threatening. If involvement of the tongue, hypopharynx, or larynx occurs, immediately discontinue GEMTESA and provide appropriate therapy and/or measures necessary to ensure a patent airway.

ADVERSE REACTIONS

Most common adverse reactions ($\geq 2\%$) reported with GEMTESA were headache, urinary tract infection, nasopharyngitis, diarrhea, nausea, and upper respiratory tract infection.

Please see accompanying full [Prescribing Information](#).





REGULATORY NOTICES

Sumitomo Pharma America, Inc. (“Sumitomo Pharma”) will report payments and transfers of value to healthcare professionals in accordance with all Federal and State reporting requirements. This may include the reporting of meals provided to office staff.

Sumitomo Pharma is not permitted to provide meals to healthcare professionals practicing in or licensed in **Vermont**.

If you are a Federal or State government employee, or affiliated with an academic institution/health system, then applicable government ethics laws or institutional requirements may prohibit you from partaking in the Sumitomo Pharma-sponsored meal. By attending this event and receiving a meal, you confirm that you are permitted to receive such benefits and have obtained the necessary approvals from your employer.

You may opt-out of the meal for this event. Please inform the program organizer if you would like to do so.

In accordance with the PhRMA Code, Sumitomo Pharma does not purchase alcohol in connection with speaker programs.

In accordance with the PhRMA Code, repeat attendance at speaker programs on the same topic is prohibited. Healthcare professionals may not attend this peer-to-peer program if they have previously attended one.

If you no longer wish to receive emails about this program, please [unsubscribe](#).



**Sumitomo
Pharma**

 is a trademark of Sumitomo Pharma Co, Ltd., used under license. SUMITOMO PHARMA is a registered trademark of Sumitomo Pharma Co., Ltd., used under license. SUMITOMO is a registered trademark of Sumitomo Chemical Co., Ltd., used under license. Sumitomo Pharma America, Inc. is a U.S. subsidiary of Sumitomo Pharma Co, Ltd. GEMTESA, and the GEMTESA logo are registered trademarks of Sumitomo Pharma Co., Ltd., used under license. 84 Waterford Drive Marlborough, MA 01752.

©2025 Sumitomo Pharma America, Inc. All rights reserved. Printed in USA. GEM-US-0567-25 11/25